{"id":"NCT00491608","sponsor":"ZymoGenetics","briefTitle":"Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis","officialTitle":"A Phase 3b, Open-Label, Single-Group Immunogenicity and Safety Study of Topical Recombinant Thrombin (rThrombin) in Surgical Hemostasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2007-06-26","resultsPosted":"2012-01-12","lastUpdate":"2012-01-13"},"enrollment":234,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Spinal Surgery","Vascular Surgery"],"interventions":[{"type":"BIOLOGICAL","name":"rThrombin","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and immune system response to recombinant thrombin when used to control bleeding in spinal and vascular surgery.","primaryOutcome":{"measure":"Number of Participants With Anti-recombinant Thrombin (rThrombin) Product Antibodies at Day 29 in Participants With and Without Anti-bovine Thrombin Product Antibodies at Baseline","timeFrame":"At Day 29","effectByArm":[{"arm":"rThrombin, 1000 IU/mL","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["20980172","19651065"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":47,"n":209},"commonTop":["Incision site pain","Procedural pain","Nausea","Constipation","Anemia"]}}